Study guide

6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD)

NAWCCB WCC Wound Care Certified Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

About the NAWCCB WCC Exam How to Use This Study Guide

2 Assessment: Skin & Tissue Foundations

1.1 Skin Anatomy, Physiology, and Barrier Function 1.2 Phases of Wound Healing & Cellular Events 1.3 Acute vs. Chronic Wounds & Etiology Classification 1.4 TIME and MEASURE Assessment Frameworks 1.5 Wound Bed Tissue Types & Periwound Assessment 1.6 Pain Assessment: Scales, Wound Pain Types, and Procedural Analgesia 1.7 Psychosocial History, Cognitive Status, and Functional Assessment 1.8 Skin Integrity Across the Lifespan: Neonatal, Pediatric, Adult, and Geriatric

3 Assessment: Diagnostic Tools & Risk Assessment

2.1 Vascular Assessment: ABI, TcPO2, and Arterial/Venous Doppler 2.2 Neuropathy & Monofilament Testing in Diabetic Patients 2.3 Pressure Injury Risk Assessment: Braden Scale Subscales & Scoring 2.4 NPIAP Pressure Injury Staging (Stages 1-4, Unstageable, DTPI) 2.5 Exudate Characterization, Biofilm (NERDS/STONEES), & Wound Culture 2.6 Laboratory Interpretation in Wound Care: Albumin, Prealbumin, ESR, A1C, CBC, and CMP 2.7 Risk Assessment Instruments Beyond Braden: Norton, Braden Q, Braden QD, Wagner, and University of Texas

4 Treatment: Dressing Selection & Debridement Modalities

3.1 Principles of Dressing Selection by Exudate & Moisture Balance 3.2 High-Absorbency Dressings: Alginates, Hydrofibers, and Foams 3.3 Barrier & Hydrating Dressings: Hydrocolloids, Transparent Films, and Hydrogels 3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey 3.5 Debridement Modalities: Sharp, Enzymatic, Autolytic, Mechanical, & Biosurgical

5 Treatment: Advanced Therapies & Specialized Management

4.1 Negative Pressure Wound Therapy (NPWT) Indications, Settings, & Precautions 4.2 Compression Therapy Protocols & ABI Safety Cutoffs 4.3 DFU Off-loading Hierarchy: TCC, RCW, and Therapeutic Footwear 4.4 Support Surfaces, Microclimate Control, & Repositioning Protocols 4.5 Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT

6 Reevaluation & Wound Healing Trajectory

5.1 Healing Trajectory Benchmarks & Percent Area Reduction (PAR) 5.2 Serial Wound Measurement, Depth Profiling, & Digital Photography 5.3 Treatment Plan Reassessment & Non-Healing Wound Escalation Triggers 5.4 Biofilm Progression & Systemic Infection Re-evaluation 5.5 Palliative Wound Management: Odor, Exudate, and Pain Control 5.6 Validated Healing Instruments: The PUSH Tool, BWAT, and Evaluating Adherence

7 Risk Reduction & Prevention Strategies

6.1 Pressure Injury Prevention: Bundles, Turning Schedules, & Heel Floating 6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD) 6.3 Infection Control, Contact Precautions, & Environmental Hygiene 6.4 Prevention of Skin Tears & Medical Adhesive-Related Skin Injuries (MARSI) 6.5 Diabetic & Venous Ulcer Recurrence Prevention Protocols 6.6 At-Risk Populations: Spinal Cord Injury, Stroke, Critical Care, and Cognitive Impairment

8 Patient & Caregiver Education

7.1 Patient & Caregiver Wound Care Teaching & Self-Management 7.2 Diabetic Foot Self-Inspection & Footwear Education 7.3 Nutritional Assessment & Dietary Interventions for Wound Healing 7.4 Off-loading Compliance & Patient Mobility Education 7.5 Recognizing Complications, Infection Signs, & When to Seek Care 7.6 Educating the Interprofessional Team & Developing Educational Media

9 Administration & Program Management

8.1 Wound Care Documentation Standards & Clinical Records 8.2 Admission Wound Screening & Present on Admission (POA) Documentation 8.3 Interdisciplinary Team Roles & Clinical Care Coordination 8.4 Quality Improvement Metrics & HAPI Tracking Programs 8.5 Wound Care Formulary Management & Resource Utilization

10 Legal, Ethical, & Scope of Practice

9.1 Informed Consent, Treatment Refusal, & Autonomy in Wound Care 9.2 HIPAA Compliance & Clinical Photography Privacy Standards 9.3 Scope of Practice Across WCC-Eligible Professions (RN, LPN, PT, OT, DPM, MD/DO, PA) 9.4 HAPI Malpractice Liability & Documentation Defense 9.5 Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care 9.6 Regulatory Compliance, Coding Standards, & Audit Protection

6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD)

Key Takeaways Explain This Topic AI

Moisture-Associated Skin Damage (MASD) encompasses four primary clinical forms: Incontinence-Associated Dermatitis (IAD), Intertriginous Dermatitis (ITD), Peristomal MASD, and Periwound MASD.

Differential diagnosis between IAD and pressure injuries is critical: IAD presents as diffuse, non-uniform erythema with superficial epidermal erosion in skin folds/buttocks without necrotic slough, whereas Stage 1 PI exhibits localized non-blanchable erythema over a bony prominence.

Effective IAD prevention requires cleansing after every incontinence episode using no-rinse, pH-balanced (pH 4.5–5.5) cleansers instead of alkaline bar soaps (pH 9.0–10.0), followed by barrier application.

Skin protectant barrier selection includes dimethicone (breathable moisture barrier), zinc oxide (thick occlusive barrier), petrolatum, and liquid cyanoacrylate/polymeric film barriers for severe skin breakdown.

Secondary cutaneous Candida albicans superinfection in MASD presents with bright red erythema, satellite pustules/papules, and requires topical antifungal powder (nystatin or miconazole) applied under barrier ointments.

Last updated: August 2026

Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD)

Moisture-Associated Skin Damage (MASD) describes skin inflammation, redness, and epidermal erosion resulting from prolonged exposure of the skin to various moisture sources, including urine, liquid stool, perspiration, wound exudate, or ostomy effluent. MASD is a major clinical challenge across acute, long-term, and home care settings. Preventing and treating MASD requires accurate clinical classification, differential diagnosis from pressure injuries, structured hygiene routines, and targeted topical barrier therapy.

Etiology & Pathophysiology of MASD

The stratum corneum serves as the skin's primary physical barrier, consisting of keratin-rich corneocytes embedded in a dense lipid matrix. Prolonged moisture exposure disrupts this architectural integrity through several physiological mechanisms:

Hyperhydration & Maceration: Excess moisture causes corneocytes to swell, disrupting cell-to-cell desmosomal attachments and lipid bilayers. Hydrated skin undergoes maceration—appearing soft, white, and wrinkled—which dramatically reduces skin tensile strength and increases vulnerability to friction and shear erosion.

Chemical Irritation & pH Alteration: Healthy skin maintains an acidic surface coat known as the acid mantle (pH 4.5 to 5.5) , which inhibits pathogen growth and regulates lipid barrier synthesis. Incontinence introduces alkaline urine and liquid fecal matter. Fecal bacteria produce urease, which converts urinary urea into ammonia, elevating skin pH ( > 7.0 >7.0 > 7.0 ).

Enzymatic Degradation: Fecal digestive enzymes—specifically pancreatic proteases (trypsin, chymotrypsin) and lipases —become highly active at elevated alkaline pH. These enzymes digest structural skin proteins and cell membrane lipids, rapidly stripping the epidermal layer.

Frictional Damage: Macerated, chemically eroded skin contacting bed linens or diapers experiences elevated coefficients of friction, resulting in superficial epidermal stripping.

Clinical Subtypes of MASD

MASD presents in four distinct clinical forms based on moisture source and anatomical location:

Incontinence-Associated Dermatitis (IAD): Erythema and erosion of the perineal, perianal, gluteal, groin, and inner thigh skin caused by contact with urine and/or stool.

Intertriginous Dermatitis (ITD / Intertrigo): Inflammation occurring in opposing skin folds (inframammary, panniculus/abdominal folds, axillary, groin, toe webs) caused by trapped perspiration, elevated warmth, and skin-on-skin friction.

Peristomal MASD: Inflammation and erosion of peristomal skin within 10 cm of an abdominal stoma (ileostomy, colostomy, urostomy) resulting from continuous contact with corrosive fecal or urinary effluent leaking beneath pouching faceplates.

Periwound MASD: Erythema, maceration, and superficial denudation of intact skin surrounding a wound margin caused by prolonged exposure to highly volume wound exudate containing matrix metalloproteinases (MMPs).

Differential Diagnosis: IAD versus Pressure Injuries

Misidentifying IAD as a pressure injury leads to improper staging, inappropriate dressing selection, and inaccurate clinical quality metrics. Clinicians must apply systematic differential diagnostic criteria:

Etiology: IAD is driven top-down by chemical irritation and moisture maceration; Pressure Injuries (PI) are driven bottom-up or top-down by mechanical pressure and shear forces.

Anatomical Location: IAD occurs diffusely across perineal, gluteal cleft, thigh, and skin fold areas exposed to moisture; PIs occur specifically over distinct bony prominences (sacrum, coccyx, ischial tuberosities, heels, trochanters).

Lesion Depth: IAD is strictly superficial (epidermis and superficial dermis erosion); PIs can extend to deep tissue, subcutaneous fat, muscle, or bone (Stage 3, Stage 4, Unstageable).

Color & Erythema: IAD exhibits diffuse, patchy, non-uniform bright red erythema with indistinct margins; Stage 1 PIs exhibit localized, well-demarcated, non-blanchable erythema.

Necrotic Tissue: IAD never presents with slough, eschar, or black necrotic tissue; Stage 3, Stage 4, and Unstageable PIs frequently contain yellow slough or dark eschar.

Structured Skin Hygiene & Cleansing Protocols

Preventing IAD mandates a standardized 3-step hygiene bundle: Cleanse, Protect, and Restore .

Cleansing Protocols

Prompt Intervention: Cleanse skin immediately following every incontinent event.

Cleanser Selection: Utilize no-rinse liquid cleansers or disposable soft cloths formulated near the skin's acidic pH ( pH 4.5 to 5.5 ). These cleansers contain mild surfactants that encapsulate fecal matter without stripping natural skin lipids.

Avoid Alkaline Soap: Traditional bar soaps and harsh body washes are strongly alkaline ( pH 9.0 to 10.0 ). They dissolve the protective acid mantle, elevate skin pH, and intensify enzymatic skin destruction. Bar soap usage is strictly contraindicated for incontinence care.

Gentle Technique: Pat or wipe skin gently with soft disposable cloths. Never scrub or rub vigorously, as mechanical friction tears fragile, macerated epidermis.

Barrier Protectants & Topical Skin Formulations

Topical skin protectants form a physical barrier against liquid, stool enzymes, and friction:

Dimethicone (1% to 3%): Silicone-based, breathable barrier cream. Forms a hydrophobic film that repels fluid while allowing vapor evaporation. Easy to apply and reapply; ideal for mild IAD or routine prevention.

Zinc Oxide (20% to 40%): Thick, opaque, highly protective barrier paste. Provides durable physical protection against harsh liquid fecal incontinence. Zinc oxide pastes are difficult to remove; clinicians must not scrub off remaining paste during routine cleansing. Simply clean the top layer of stool off the paste and apply a fresh layer over top.

Petrolatum Ointment: Petroleum jelly-based occlusive barrier. Provides excellent moisture protection but can clog absorbent diaper linings (reducing diaper absorbency).

Liquid Acrylate / Cyanoacrylate Polymeric Films: Non-stinging, solvent-free liquid barrier films or cyanoacrylate skin protectants. Form a durable, transparent, waterproof polymer layer that adheres tightly to denuded skin, lasting 48 to 72 hours. Excellent for severe, painful IAD with superficial erosion.

Management of Secondary Cutaneous Fungal Infections

The warm, moist environment of MASD and IAD frequently promotes secondary cutaneous fungal superinfections, most commonly Candida albicans .

Clinical Presentation of Cutaneous Candidiasis

Bright, beefy-red erythema in skin folds or perineum.

Pathognomonic Satellite Lesions: Distinct small red papules and fluid-filled pustules scattered just beyond the main advancing erythematous margin.

Severe burning, itching (pruritus), and tenderness.

Antifungal Treatment Protocol

Topical Antifungal Powders: Apply a thin layer of topical antifungal powder containing miconazole 2% , nystatin , or clotrimazole 1% directly to clean, dry skin folds and perineum. Gently rub the powder into the skin.

Barrier Application over Powder: Apply a thin layer of breathable dimethicone or petrolatum barrier cream over the antifungal powder to seal the medication against the skin while repelling moisture.

Avoid Thick Pastes: Avoid heavy zinc oxide pastes when treating active fungal infections, as thick pastes trap moisture beneath and prevent antifungal powder contact.

Clinical Feature Incontinence-Associated Dermatitis (IAD) Stage 1 Pressure Injury Stage 2 Pressure Injury

Primary Cause Top-down chemical moisture & enzyme erosion Bottom-up mechanical pressure & shear ischemia Mechanical pressure, shear, or friction forces

Anatomical Site Diffuse: perineum, buttocks, inner thighs, folds Localized directly over a bony prominence Localized over a bony prominence or device site

Lesion Boundaries Diffuse, irregular, patchy, indistinct margins Well-demarcated, distinct localized area Well-demarcated, distinct ulcer perimeter

Erythema Type Diffuse bright red; May blanch under pressure Localized non-blanchable erythema Non-blanchable surrounding periwound erythema

Depth of Tissue Loss Superficial (epidermis/dermis erosion only) Intact skin; no epidermal loss Partial-thickness loss of dermis; shallow open ulcer

Slough / Necrotic Tissue Absolutely absent Absolutely absent Absolutely absent (slough indicates Stage 3/4)

Loading diagram... MASD Clinical Assessment & Topical Barrier Selection Flowchart